Search results
Results from the WOW.Com Content Network
Shire plc was a UK-founded Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019.
In February 2017, Takeda acquired Ariad Pharmaceuticals for $5.2 billion, expanding the company's oncology and hematology divisions. [26] In January 2018, the company acquired stem cell therapy developer TiGenix for up to €520 million ($632 million). [27] In January 2019, Takeda acquired Shire for more than US$50 billion.
In 2016 the company was acquired by Shire for $32 billion. [9] Subsequently, Shire was acquired by Takeda Pharmaceutical Company for $62 billion in January 2019. [ 10 ] [ 11 ]
LONDON/TOKYO (Reuters) - Takeda Pharmaceutical <4502.T> agreed to buy London-listed Shire (SHP.L) for 45.3 billion pounds ($61.50 billion) on Tuesday, marking the biggest deal yet in a wave of ...
As part of the merger agreement, Shire shareholders will be entitled to receive $30.33 in cash for each Shire share owned and 0.839 shares either 0.839 new Takeda shares or 1.678 new Takeda ADSs ...
He joined Takeda after it acquired Shire for $62 billion in 2019. In recent years, he says the environment for pharmaceutical companies has become more volatile.
Takeda Pharmaceutical: Shire: 58.2 71 First bid, unanimously rejected by the Shire Board, who concluded that it significantly undervalue the company, its growth prospects as well as pipeline. [24] 13 2014 Valeant Pharmaceuticals: Allergan, Inc: 54 70 Valeant had pursued Botox-maker Allergan for six months.
The tentative agreement would represent a victory for Takeda following a pursuit that started on March 28, when the company said it was considering a bid for Shire.